Agomab Therapeutics
AgomAb Therapeutics is a Company is developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues.
Agomab Therapeutics has raised €240M across 4 funding rounds from 10 investors, most recently a Series D+ round in Oct 2024. Based in Ghent, Belgium; founded 2017; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€240M
€239,540,878
Funding rounds
4
Investors
10
distinct backers
Active since
2019-04
latest 2024-10
Funding by year
EUR raised per yearAgomab Therapeutics — funding by year — interactive chart.
Data table
| Agomab Therapeutics — funding by year | |
|---|---|
| 2019 | €21M |
| 2022 | €41M |
| 2023 | €95M |
| 2024 | €83M |
Signals
High confidenceRaise-next likelihood26
base rate 53% for Series D+
- ▼ Past typical raise window
- ▼ Low backer re-investment
Exit likelihood15
base rate 11% (2+ rounds)
- ▲ €100M+ raised
- ▲ 4 rounds raised
- ▲ 9y since founding (typical exit age)
- ▼ No recent equity round (debt-only or quiet)
Timing: overdue vs cohort gap · momentum flat. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
4 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2024-10-25 | Series D+ | €83M | Asabys Partners,Existing investors,Invus,Sanofi Ventures | View deal → |
| 2023-10-13 | Series C | €95M | Fidelity Management & Research Company LLC | View deal → |
| 2022-07-13 | Series B | €41M | Pfizer Ventures,Sabadell Asabys,Walleye Capital | View deal → |
| 2019-04-01 | Series A | €21M | Advent France Biotechnology,V-Bio Ventures | View deal → |
Investors
10Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Imec€2.5BBelgium · Deeptech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Kpler€1.0BBelgium · Software
Global coverage: FundingData